Article

Access to the text (HTML) Access to the text (HTML)
PDF Access to the PDF text
Advertising


Access to the full text of this article requires a subscription.
  • If you are a subscriber, please sign in 'My Account' at the top right of the screen.

  • If you want to subscribe to this journal, see our rates



Journal of the American Academy of Dermatology
Volume 43, n° 4
pages 683-686 (octobre 2000)
Doi : 10.1067/mjd.2000.106510
Therapeutic update: Use of risperidone for the treatment of monosymptomatic hypochondriacal psychosis
 

Kathleen B. Elmer, MajUSAF, MC, FS a, Rita M. George, MajUSAF, MC, FS b, Karen Peterson, MajUSAF, MC a
Yokota AB, Japan, and Langley AFB, Virginia 
From the Medical Service, Yokota AB,a and the Dermatology Service, Langley AFB.b 

Abstract

Monosymptomatic hypochondriacal psychoses such as delusions of parasitosis are often difficult to treat. For the past two decades, pimozide has been considered the drug of choice. Although a few controlled studies have been done to support the efficacy of pimozide, the recommendation of treatment of choice is largely based on case reports. Pimozide has significant side effects, including cardiac and extrapyramidal abnormalities, which are of most concern in the treatment of the elderly. Although pimozide does appear to be effective in some cases of somatic delusional disorders, newer antipsychotics such as risperidone have also been shown to be beneficial in treating this perplexing cluster of disorders. Risperidone is generally considered safer than pimozide and should be considered as first-line therapy for monosymptomatic hypochondriacal psychoses. (J Am Acad Dermatol 2000;43:683-6.)

The full text of this article is available in PDF format.

 Reprints not available from authors.
 J Am Acad Dermatol 2000;43:683-6.


Top of the page

© 2000  American Academy of Dermatology, Inc. Published by Elsevier Masson SAS@@#104157@@
EM-CONSULTE.COM is registrered at the CNIL, déclaration n° 1286925.
As per the Law relating to information storage and personal integrity, you have the right to oppose (art 26 of that law), access (art 34 of that law) and rectify (art 36 of that law) your personal data. You may thus request that your data, should it be inaccurate, incomplete, unclear, outdated, not be used or stored, be corrected, clarified, updated or deleted.
Personal information regarding our website's visitors, including their identity, is confidential.
The owners of this website hereby guarantee to respect the legal confidentiality conditions, applicable in France, and not to disclose this data to third parties.
Close
Article Outline
You can move this window by clicking on the headline
@@#110903@@